BTIG lowered the firm’s price target on Intuitive Surgical (ISRG) to $529 from $571 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results for MedTech industry. Headlines weighing on sentiment in MedTech include cuts to Medicaid, ACA subsidies not being renewed, and concerns on the broader economy, as investors fear that fewer patients may seek out medical treatment, while the latest threat of high tariffs on China imports adds to uncertainty, but even so, the results in Q3 may prove better than feared as much of the headline risk is slated to take effect further in the future, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical announces U.S. FDA cleared software advancements
- Looking for Exposure to UnitedHealth Stock (UNH)? Here’s How to Buy Without the Risk
- QQQ ETF News, 10/2/2025
- Intuitive Surgical’s Growth Potential in Endoluminal Robotics: A Buy Rating Analysis
- Intuitive Surgical’s Strategic Innovations and Market Position Drive Buy Rating